Start free
Workflows

Graveyard analysis

Find out why drugs like yours failed: for every one that was discontinued, Sleuth works out why it ended and whether your design fixes that failure.

Run Graveyard analysis

In Studio: Graveyard Analysis

Use it when

  • You're choosing where to take a program or platform next: an organ, an indication, a target, or a modality.
  • You need to show a board or partner that you won't repeat what ended the drugs before yours.

What to have ready

What your program or platform does, the decision you face, and the options you're weighing, such as which organ, indication, or target to go after next. The options can also be assets you'd license in.

How it runs

  1. Describe your program. What it does and the options in front of you.
  2. Decide what counts. Choose how to weigh each option: how often its drugs failed on their own data, whether your design fixes that failure, and how early a first trial could show it.
  3. Shape the plan. Sleuth shows its three steps: find every discontinued drug like yours, find out why each one ended, and compare them with yours. Widen what counts as like yours before it runs.
  4. Get the analysis. A priority for each option, what your first trial has to show, and a table of every discontinued drug with its cause.

What you get

Your questionWhat Sleuth gives you
Which drugs like ours were discontinued?Every drug like yours that entered the clinic, each counted once with its status checked, and for each discontinued one, the stage it reached.
Why did each one end?One main cause for each, from the sponsor's statement or its last reported data, so failures on a drug's own data stay apart from portfolio and financing decisions.
Does our design fix that failure?Each option you're weighing, set against how its drugs failed and marked as fixing that failure or exposed to it, with what your first trial would have to show.

A finished example

Where should a liver siRNA company go next? Sleuth says skeletal muscle. 233 discontinued RNA drugs, sorted by organ and cause. Every muscle failure on data was a delivery shortfall, the problem the company already solves in the liver. See the full example

Questions

Is there a reason for every discontinued drug?

Where the sponsor gave one, Sleuth uses it. Where it didn't, Sleuth infers the cause from the last reported data and labels it inferred.

Does it separate business decisions from failures?

Yes. Each drug gets one main cause, so a portfolio or financing decision stays apart from a failure on the drug's own data. In the example, portfolio decisions were the most common single cause.

Can the options be targets or modalities?

Yes. The options can be indications, organs, targets, modalities, or assets you'd license in.

Does it cover drugs still in development?

Yes. Sleuth compares your program with the drugs still in development too, so you can see who's already working on the failure you'd fix.

What does it say my first trial has to show?

For each option, Sleuth states the requirement. In the example, that's drug levels and knockdown in muscle biopsies from the first patients, at a tolerable dose.

Credits

The plan shows the size of the job before anything runs: rows times analytical columns is the credits it will use. How credits work

Next questions on the same project

Indication selection finds where you'd be first. Asset scouting finds an asset to bring in. Standard of care evolution picks the patients for a first pivotal trial.